Loading clinical trials...
Loading clinical trials...
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies
Conditions
Interventions
PEN-866 Sodium
fluorouracil
+2 more
Locations
16
United States
Highlands Oncology Group
Springdale, Arkansas, United States
Sarah Cannon Reasearch Institute at HealthONE
Denver, Colorado, United States
Florida Cancer Specialists - South
Fort Myers, Florida, United States
Florida Cancer Specialists - North
St. Petersburg, Florida, United States
Florida Cancer Specialists - East
West Palm Beach, Florida, United States
National Institutes of Health / National Cancer Institute
Bethesda, Maryland, United States
Start Date
August 29, 2017
Primary Completion Date
January 1, 2023
Completion Date
June 1, 2023
Last Updated
February 17, 2022
NCT07218315
NCT07227402
NCT03206060
NCT06844383
NCT05268614
NCT05889195
Lead Sponsor
Tarveda Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions